Geron GERN
Geron FY 2020: revenue $253K; diluted EPS −$0.28
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001564590-21-012493
- Document
- 10-K
Key figures from this report
These are the numbers Geron reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$253KNo year-earlier figure tagged10-K income statement, on EDGAR
- Net income−$75.6MNo year-earlier figure tagged10-K income statement, on EDGAR
- Diluted EPS−$0.28No year-earlier figure tagged10-K income statement, on EDGAR
- Cash and cash equivalents$9.9MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$66.7MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Intellia Therapeutics NTLA public float $869M, Jun 30, 2025
- Wave Life Sciences WVE public float $851M, Jun 30, 2025
- CorMedix CRMD public float $910M, Jun 30, 2025
- Niagen Bioscience NAGE public float $814M, Jun 30, 2025
- Nurix Therapeutics NRIX public float $808M, May 30, 2025
